Bullish option flow detected in GSK (GSK) Pharma with 3,057 calls trading, 1.1x expected, and implied vol increasing over 4 points to 29.80%. Feb-25 34 calls and 1/31 weekly 34 calls are the most ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

But GSK is only looking at the business Walmsley said the “we don’t need it and we won’t overpay for it," - and also pledged that its most important division, pharma, would not lose out on ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.